Quick Answer
Regen BioPharma Inc reported R&D Expense of $11.7 thousand for fiscal year 2025.
Regen BioPharma Inc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $11.7K | -92.4% |
| 2024 | $153.7K | -27.6% |
| 2023 | $212.3K | +34.2% |
| 2022 | $158.1K | +330.8% |
| 2021 | $36.7K | +176.3% |
| 2020 | $13.3K | -70.9% |
| 2019 | $45.6K | -87.8% |
| 2018 | $374.4K | -67.4% |
| 2017 | $1.15M | +71.3% |
| 2016 | $671.1K | +137.7% |
| 2015 | $282.3K | +1082.8% |
| 2014 | $23.9K | +184.3% |
| 2013 | $8.4K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $210.0K | — | — |
| December 31, 2024 | $0.00 | -100.0% | -100.0% |
| June 30, 2024 | $32.5K | -27.8% | -19.0% |
| March 31, 2024 | $40.1K | +10.1% | -15.6% |
| December 31, 2023 | $47.5K | -50.2% | +5.6% |
| June 30, 2023 | $45.0K | +44.9% | +23.5% |
| March 31, 2023 | $36.4K | +33.1% | -61.8% |
| December 31, 2022 | $95.5K | +169.7% | +207.5% |
- Regen BioPharma Inc showed a decrease of -92.4% in R&D Expense compared to the prior fiscal year.
- Over the 2013–2025 period, Regen BioPharma Inc’s r&d expense has grown by 39.7% (from $8.4 thousand to $11.7 thousand).
- The most recent figure is from Regen BioPharma Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on December 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: